GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update

Phase 2 clinical trial of temelimab against neuropsychiatric syndromes of Post-COVID :


Recruitment completed in November 2023;



Topline results planned for end of June 2024.







Cash position...

Related Keywords

United States ,France ,Switzerland ,Geneva ,Genè ,Swiss ,French , ,Research Tax Credit ,European Investment Bank ,Research Development ,Swiss Federal Office Of Public Health ,French Research Tax Credit ,European Union ,Regulatory News ,Euronext Paris ,Swiss Federal Office ,Public Health ,Lateral Sclerosis ,Statutory Auditors ,Geneuro Innovation ,Tax Credit ,Markets ,